Skip to content
Sexuality – Lifestyle
Author:
Elevar Therapeutics
Elevar Therapeutics Announces Three Abstracts Accepted for Presentation at ESMO Congress 2026
July 27, 2026
Elevar Therapeutics Receives FDA Complete Response Letter for Combination of Rivoceranib and Camrelizumab as a First-line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
July 10, 2026
Elevar Therapeutics Announces First Patients Dosed in Phase 2 Study of Lirafugratinib Among Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
June 22, 2026
Elevar Therapeutics Announces FDA Acceptance for Review of New Drug Application for Lirafugratinib as Second-line Cholangiocarcinoma Treatment
March 30, 2026